溴隐亭降糖及减重的研究进展

Update on glycemic control and weight reduction with bromocriptine treatment

溴隐亭为多巴胺受体激动剂。近年来,研制出的溴隐亭快速释放剂型——甲磺酸溴隐亭片(Cycloset),已被美国食品和药品管理局(FDA)批准用于治疗T2DM。作为一种作用于中枢神经系统的降糖药,其可通过改善糖脂代谢,减轻IR而发挥降糖作用,为T2DM的治疗另辟蹊径。另外,本药对于肥胖的治疗,已取得了显著的效果。

Recently, timed-release bromocriptine （cycloset）, a sympatholytie dopamine D2 receptor agonist, has been approved by the U.S. Food and Drug Administration （FDA） for the treatment of T2DM. Bromocriptine acts on the central nervous system and improves insulin sensitivity through its regulation on glycolipid metabolism, opening a new way for the treatment of T2DM. In addition, it may be used for obesity for weight reduction and the effect is good.